A New Weapon Against Implant Infections Takes Shape

Peptide therapies advance into pivotal Phase 2/3 trials, pointing to a new way to prevent implant infections if results and approvals follow

2 Feb 2026

Peptide-based therapies aimed at preventing infections linked to surgical implants are moving into pivotal clinical trials, marking a potential shift in how hospitals address some of their most costly complications.

Peptilogics, a US biotech group, has advanced its lead peptide therapy into Phase 2/3 trials following a recent funding round. The move reflects rising interest in approaches that sit outside conventional antibiotics, particularly as infection risk grows alongside the rising number of joint replacement surgeries.

Hundreds of thousands of hip and knee implants are carried out each year in the US. While most patients recover without incident, a small proportion develop infections that are difficult to treat and expensive for health systems. These infections often require repeat operations and prolonged care.

A key challenge is the ability of bacteria to form biofilms on implant surfaces. These protective layers make infections resistant to standard antibiotics and allow bacteria to persist despite treatment, extending recovery times and increasing costs.

Peptilogics’ therapy is designed to address this problem directly. Rather than targeting bacteria systemically, it uses engineered peptides applied at the surgical site to disrupt bacterial defences before infections become established. By acting locally, the approach aims to reduce the need for broader antibiotic use and limit the risk of resistance.

Industry executives and investors view this as part of a wider rethink of infection prevention in surgery. Preventing bacteria from attaching to implants could lower clinical risk and reduce long-term costs, provided trials demonstrate clear benefits.

The latest funding allows the company to test its technology at a larger scale, at a time when demographic trends are adding pressure to healthcare systems. An ageing population and rising surgical volumes are increasing demand for more effective infection control, while concerns about antimicrobial resistance continue to grow.

The implications could extend beyond orthopaedics. If late-stage trials are successful, similar peptide-based strategies could be applied to trauma hardware, cardiovascular devices and other implants prone to infection.

Significant hurdles remain, including regulatory approval, proof of economic value and adoption by surgeons and hospitals. Even so, the progression into pivotal trials suggests peptide therapies are becoming a more serious contender in efforts to prevent implant-related infections.